| Form 1-Z Issuer Information |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-Z EXIT REPORT UNDER REGULATION A | OMB APPROVAL |
| OMB Number: 3235-0723 Estimated average burden hours per response: 1.5 |
1-Z: Filer Information
| Issuer CIK | 0001959708 |
| Issuer CCC | XXXXXXXX |
| File Number | |
| Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? | 
Yes
No
|
| Successor File Number |
| Is this a LIVE or TEST Filing? |
LIVE
TEST
|
| Is this an electronic copy of an official filing submitted in paper format? |  |
| Would you like a Return Copy? | |
Submission Contact Information
| Name | |
| Phone | |
| E-Mail Address |
| Notify via Filing Website only? | |
1-Z: PRELIMINARY INFORMATION
| Exact name of issuer as specified in the issuer's charter | Algernon Neuroscience Inc. |
| Address of Principal Executive Offices | |
| Address 1 | 400-601 West Broadway |
| Address 2 | |
| City | Vancouver |
| State/Country |
BRITISH COLUMBIA, CANADA
|
| Mailing Zip/ Postal Code | V5Z 4C2 |
| Phone | 604-398-4175 |
| Commission File Number(s) | 024-12117 |
1-Z: PART I Summary Information Regarding the Offering and Proceeds
Summary Information
| Date of qualification of the offering statement | 03-08-2023 |
| Date of commencement of the offering | 03-08-2023 |
| Amount of securities qualified to be sold in the offering | 12000000 |
| Amount of securities sold in the offering | 0 |
| Price per security: |
$
0.0000 |
| The portion of aggregate sales attributable to securities sold on behalf of the issuer |
$
0.00 |
| The portion of aggregate sales attributable to securities sold on behalf of selling securityholders: |
$
0.00 |
Fees in connection with this offering and names of service providers.
| Underwriters - Name of Service Provider | Underwriters - Fees |
$
0.00 | |
| Sales Commissions - Name of Service Provider | Sales Commissions - Fee |
$
0.00 | |
| Finders' Fees - Name of Service Provider | Finders' Fees - Fees |
$
0.00 | |
| Accounting or Audit - Name of Service Provider | Smythe LLP | Accounting or Audit - Fees |
$
28571.00 |
| Legal - Name of Service Provider | Sheppard Mullin Richter & Hampton LLP | Legal - Fees |
$
64128.00 |
| Promoters - Name of Service Provider | Promoters - Fees |
$
0.00 | |
| Blue Sky Compliance - Name of Service Provider | Dalmore Group LLC | Blue Sky Compliance - Fees |
$
25000.00 |
| CRD Number of any broker or dealer listed | 0 |
| Net proceeds to the issuer |
$
0.00 |
| Clarification of responses (if necessary): | N/A |
1-Z: PART II Certification of Suspension of Duty to File Reports
Certification
| Title of each class of securities covered by this Form | Class A Common Shares |
| Commission File Number(s) | 024-12117 |
| Approximate number of holders of record as of the certification date | 1 |
1-Z: Signature
Signature
Pursuant to the requirements of Regulation A,
| Cik | 0001959708 |
| (Name of issuer as specified in charter) | Algernon Neuroscience Inc. |
certifies that it meets all of the conditions for termination of Regulation A reporting specified in Rule 257(d) and that there are no classes of securities other than those that are the subject to this Form 1-Z regarding which the issuer has Regulation A reporting obligations.
| (Name of issuer as specified in charter) | Algernon Neuroscience Inc. |
| By | James Kinley |
| Date | 12-11-2023 |
| Title | Chief Financial Offficer |